Therapeutic Targeting TFE3 in Translocation Renal Cell Carcinoma
Abstract
This project addresses specific Areas of Emphasis including "rare cancer" and "targeted therapies." Translocation renal cell carcinoma is a rare type of kidney cancer in the adult but more common in children. This type of tumor is quite aggressive, and the standard therapies utilized for the most common types of kidney cancer do not work. Over the years, several studies have identified a specific alteration in the genome of these tumors. Briefly, the DNA undergoes a "cut and paste" phenomenon that leads to the expression of malignant proteins, called TFE3-Os. Our lab has recently established the growth of one of these tumors in mice and determined that these malignant proteins are responsible for the aggressive behavior of these cancers. Our proposal plans to further understand how these malignant proteins work in the translocation renal cell carcinoma and to identify some potential drugs that can be eventually tested in patients. Taken together, the principal objective of the proposed research is to improve our understanding of these rare but deadly kidney cancers. Overall, this study will help the patients with translocation kidney cancer in the near future. In particular, the proposed research is relevant to active duty Service members, their families, Veterans, and other military beneficiaries by providing new therapeutic tools for a rare disease on the rise because of our increased capability of its diagnosis.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Oct 29, 2018
- Source ID
- W81XWH1810586
Entities
People
- Roberto Pili
Organizations
- Indiana University – Purdue University Indianapolis
- United States Army